Trial
NCT03907072
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Wave Life Sciences USA, Inc.
Collaborators
—
Condition
Duchenne Muscular Dystrophy
Intervention
WVE-210201 (suvodirsen)
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-05-20